Business
Novavax Reports Second Quarter 2022 Financial Results and Operational Highlights
Received FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults; with
About this update from Novavax, Inc.
[{"type":"text","content":"Received FDA EUA and CDC recommendation for NVX-CoV2373, marking the first protein-based COVID-19 vaccine authorized in the U.S. for adults; with immunizations underwayNuvaxovid™ and Covovax™ authorized for adults in 43 countries, with booster authorizations in Japan, Australia and New Zealand as well as, adolescent authorizations in the EU, Australia, India, Japan, and ThailandOver 73 million doses delivered globally to date Progressing variant program with top-line clinical data for Omicron expected near the end of the third quarter of 2022Adjusted revenue guidance to $2 billion to $2.3 billionCompany to host conference call today at 4:30 p.m. ETGAITHERSBURG, Md., Aug. 8, 2022 /PRNewswire/ -- Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the second quarter ended June 30, 2022.\n\"We are pleased with our progress since the start of the second quarter, which importantly included delivering our vaccine to the U.S. market with immunizations underway,\" said Stanley C. Erck, President and Chief Executive Officer, Novavax. \"With over 23 million doses delivered since the start of the third quarter, we are distributing our vaccine globally and have gained positive momentum as we move into the remainder of 2022 and into 2023. Through continued expansions to our label for adolescents and boosting and our vaccine's competitive product profile, we are confident it will play an important role in the long-term COVID-19 landscape.\"\nSecond Quarter 2022 and Recent Highlights\nProgressed COVID-19 Global Regulatory Strategy \nReceived Emergency Use Authorization (EUA) from United States (U.S.) Food and Drug Administration (FDA) with label expansion underway, marking first protein-based COVID-19 vaccine available for use domesticallyAuthorized for primary series in adults 18 and older with unanimous recommendation received from U.S. Centers for Disease Control and Prevention (CDC)Planned submission for boosting data from PREVENT-19 Phase 3 trial in August of 2022Nuvaxovid or Covovax authorized in 43 countries for primary series in adults 18 and older, with additional label expansions received and underway in several geographiesAuthorized for boosting in adults 18 and ...